文献情報
- トップページ >
- 文献情報
NEW
Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence
Clara Cortell Fuster, et al. J Dermatolog Treat. 2021 Apr 6;1-7.
PubMed
Clara Cortell Fuster, et al. J Dermatolog Treat. 2021 Apr 6;1-7.
PubMed
Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex
Takashi Hatano, et al. Orphanet J Rare Dis. 2020 Jun 1;15(1):133.
PubMed
Takashi Hatano, et al. Orphanet J Rare Dis. 2020 Jun 1;15(1):133.
PubMed
Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial.
Wataya-Kaneda M, et al. Dermatol Ther (Heidelb). 2020 May 8.
PubMed
Wataya-Kaneda M, et al. Dermatol Ther (Heidelb). 2020 May 8.
PubMed
Early Sirolimus Gel Treatment May Diminish Angiofibromas and Prevent Angiofibroma Recurrence in Children With Tuberous Sclerosis Complex.
Okanishi T, et al. Front Med (Lausanne). 2020 Jan 22;7:1.
PubMed
Okanishi T, et al. Front Med (Lausanne). 2020 Jan 22;7:1.
PubMed
Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.
Wataya-Kaneda M, et al. JAMA Dermatol. 2018; 154（7）: 781-788
PubMed
Wataya-Kaneda M, et al. JAMA Dermatol. 2018; 154（7）: 781-788
PubMed
Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
Wataya-Kaneda M, et al. JAMA Dermatol. 2017; 153（1）: 39-48
PubMed
Wataya-Kaneda M, et al. JAMA Dermatol. 2017; 153（1）: 39-48
PubMed
Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.
Wataya-Kaneda M, et al. JAMA Dermatol. 2015; 151（7）: 722-730
PubMed
Wataya-Kaneda M, et al. JAMA Dermatol. 2015; 151（7）: 722-730
PubMed
Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus.
Nathan N, et al. J Am Acad Dermatol. 2015; 73（5）: 802-808
PubMed
Nathan N, et al. J Am Acad Dermatol. 2015; 73（5）: 802-808
PubMed
Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.
Knopfel N, et al. Actas Dermosifiliogr. 2014; 105（8）: 802-803
PubMed
Knopfel N, et al. Actas Dermosifiliogr. 2014; 105（8）: 802-803
PubMed
Successful treatment of subungual fibromas of tuberous sclerosis with topical rapamycin.
Muzic JG, et al. JAMA Dermatol. 2014; 150（9）: 1024-1025
PubMed
Muzic JG, et al. JAMA Dermatol. 2014; 150（9）: 1024-1025
PubMed
A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex.
Wataya-Kaneda M, et al. Arch Dermatol. 2012; 148（1）: 138-139
PubMed
Wataya-Kaneda M, et al. Arch Dermatol. 2012; 148（1）: 138-139
PubMed
Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient.
Micozkadioglu H, et al. Ren Fail. 2010; 32（10）: 1233-1236
PubMed
Micozkadioglu H, et al. Ren Fail. 2010; 32（10）: 1233-1236
PubMed
Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
Tarasewicz A, et al. Transplant Proc. 2009; 41（9）: 3677-3682
PubMed
Tarasewicz A, et al. Transplant Proc. 2009; 41（9）: 3677-3682
PubMed
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.
Rauktys A, et al. BMC Dermatol. 2008; 8 : 1.
PubMed
Rauktys A, et al. BMC Dermatol. 2008; 8 : 1.
PubMed
